3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Sorafenib
121
Nivolumab
36
pembrolizumab
32
Bevacizumab
28
lenvatinib
27
Doxorubicin
23
Radiosurgery
21
Radiofrequency Ablation
20
Oxaliplatin
20
Hepatectomy
18
Fluorouracil
15
Capecitabine
15
Magnetic Resonance Spectroscopy
14
atezolizumab
13
Leucovorin
13
Cisplatin
13
Gemcitabine
11
Erlotinib Hydrochloride
11
tislelizumab
9
Sirolimus
9
Radiotherapy
9
Irinotecan
9
Ipilimumab
9
cabozantinib
8
Liver Transplantation
8
regorafenib
7
Ramucirumab
7
Folfox protocol
7
Embolization, Therapeutic
7
sintilimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Hepatocellular
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled